Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cangjing Biotechnology is a Shanghai-based biopharmaceutical company specializing in the development of mRNA-based therapeutics and vaccines. Founded by Dr. Lin Jinhui, a former Moderna scientist, the company leverages its proprietary lipid nanoparticle (LNP) delivery platform and advanced mRNA sequence optimization technology to target infectious diseases and oncology. Its lead candidate, CJ-101, is an mRNA vaccine for COVID-19 that has progressed into clinical evaluation. Additionally, the company is advancing programs for respiratory syncytial virus (RSV), seasonal influenza, and personalized cancer vaccines. Cangjing aims to provide highly efficient and scalable solutions for global health challenges through its integrated R&D capabilities. The firm is backed by leading investors such as GL Ventures and Sequoia China.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cang Jing.